Atossa Therapeutics, Inc. (ATOS)
| Market Cap | 25.95M -74.4% |
| Revenue (ttm) | n/a |
| Net Income | -37.71M |
| EPS | -4.34 |
| Shares Out | 9.98M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 96,103 |
| Open | 2.540 |
| Previous Close | 2.560 |
| Day's Range | 2.430 - 2.690 |
| 52-Week Range | 1.700 - 19.350 |
| Beta | 1.25 |
| Analysts | Buy |
| Price Target | 18.67 (+618.08%) |
| Earnings Date | Aug 7, 2026 |
About ATOS
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator and selective estrogen receptor degrader currently in Phase 2 clinical development for the treatment and reduction of risk of breast cancer, as well as in other therapeutic areas. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for ATOS stock is "Buy." The 12-month stock price target is $18.67, which is an increase of 618.08% from the latest price.
News
Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update
SEATTLE, Aug. 7, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other area...
Atossa Therapeutics Quarterly report: Q2 2026
Atossa Therapeutics has published its Q2 2026 quarterly earnings report on August 7, 2026.
Atossa Therapeutics Earnings release: Q2 2026
Atossa Therapeutics released its Q2 2026 earnings on August 7, 2026, summarizing the period's financial results.
Atossa Therapeutics Announces Publication of Novel (Z)-Endoxifen-Related Compounds Demonstrating Potent Anti-Cancer Activity in ER-Positive Breast Cancer
Peer-reviewed preclinical study published in npj Breast Cancer identifies new chemical entities with activity in ESR1-mutant models Findings suggest potential for combination with abemaciclib SEATTLE,...
Atossa Therapeutics Announces Presentation of Mechanism-Driven (Z)-Endoxifen Data in McCune-Albright Syndrome at AACR Special Conference on Rare Cancers
Preclinical Data Poster Highlights Dual Estrogen Receptor and PKC-β/AKT Pathway Modulation as a Potential Therapeutic Strategy for Estrogen-Driven Pathology in McCune-Albright syndrome SEATTLE, July 2...
Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds
$4.5 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon exercise in full of warrants SEATTLE, June 12, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasd...
Atossa Therapeutics Announces Registered Direct Offering of up to $16.5 Million in Gross Proceeds
$4.5 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon exercise in full of warrants SEATTLE, June 11, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasd...
Atossa Therapeutics Announces ASCO 2026 Abstracts Highlighting (Z)-Endoxifen Activity Across ESR1 Mutations and Ongoing EVANGELINE Phase 2 Trial
Preclinical Data Abstract Demonstrates Robust Estrogen Receptor (ER) Inhibition in ESR1-Mutant Breast Cancer Models at Clinically Relevant Concentrations Trial-in-Progress Abstract Details Ongoing Pha...
Atossa Therapeutics Announces Acceptance of Manuscript Highlighting Utrophin-Modulation Potential of (Z)-Endoxifen in Duchenne Muscular Dystrophy
Review article accepted for publication in Degenerative Neurological and Neuromuscular Disease and builds on Atossa's previously published Duchenne Muscular Dystrophy (DMD) research SEATTLE, May 20, 2...
Atossa Therapeutics Transcript: Status update
Adaptive platform trials like I-SPY are accelerating breast cancer drug development, focusing on early endpoints and individualized therapies. Endoxifen demonstrates strong efficacy and tolerability, with ongoing trials exploring its use in combination regimens. Regulatory engagement and personalized prevention strategies are driving faster, more patient-centered progress.
Atossa Therapeutics to Host Virtual KOL Event Featuring Dr. Laura Esserman to Discuss Development of (Z)-Endoxifen in ER-Positive Breast Cancer
Event to feature Dr. Laura Esserman, internationally recognized surgical oncologist, breast cancer expert, and founder and principal investigator of the I-SPY Trials SEATTLE, May 14, 2026 /PRNewswire/...
Atossa Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
SEATTLE, May 8, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas...
Atossa Therapeutics Quarterly report: Q1 2026
Atossa Therapeutics has published its Q1 2026 quarterly earnings report on May 8, 2026.
Atossa Therapeutics Earnings release: Q1 2026
Atossa Therapeutics released its Q1 2026 earnings on May 8, 2026, summarizing the period's financial results.
Atossa Therapeutics Announces Publication of KARISMA Endoxifen Trial Demonstrating Significant Reduction in Mammographic Breast Density in Healthy Premenopausal Women
Peer-reviewed data support (Z)-endoxifen's (Endoxifen) potential as a differentiated breast cancer risk prevention candidate by marked reduction of mammographic breast density (MBD) Doses of both 1 mg...
Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for McCune-Albright Syndrome
Designation expands (Z)-endoxifen program into rare pediatric endocrine disorder and qualifies Atossa for a Priority Review Voucher award upon approval SEATTLE, May 4, 2026 /PRNewswire/ -- Atossa Ther...
Atossa Therapeutics Proxy statement: Proxy filing
Atossa Therapeutics filed a proxy statement on March 30, 2026, providing details for shareholder voting and corporate governance matters.
Atossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides a Corporate Update
SEATTLE, March 25, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other ar...
Atossa Therapeutics Earnings release: Q4 2025
Atossa Therapeutics released its Q4 2025 earnings on March 25, 2026, summarizing the period's financial results.
Atossa Therapeutics Annual report: Q4 2025
Atossa Therapeutics has published its Q4 2025 annual report on March 25, 2026.
Atossa Therapeutics Proxy statement: Proxy filing
Atossa Therapeutics filed a proxy statement on March 20, 2026, providing details for shareholder voting and corporate governance matters.
Atossa Therapeutics Strengthens Clinical Leadership Team with the Addition of Two Experienced Biopharma Executives
Kathy Puyana Theall, M.D. and Adebola Giwa, M.D.
Atossa Therapeutics Presents Clinical Trial Update Highlighting (Z)-Endoxifen Research at the 2026 MDA Clinical & Scientific Conference
Study Highlights Findings that (Z)-endoxifen Restores Muscle Performance and Lowers Damage Biomarkers in mdx5Cv Dystrophic Mice SEATTLE, March 12, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasda...
Atossa Therapeutics Issues Letter to Shareholders Highlighting 2025 Accomplishments and 2026 Outlook
SEATTLE, Feb. 11, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other...
Atossa Therapeutics Slides: Corporate presentation
Atossa Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on February 11, 2026.